HeraMED Ltd managing director and CEO Anoushka Gungadin joins Proactive’s Tylah Tully after the company raised $3.1 million in a two-tranche placement targeting sophisticated and professional investors.
Priced at 1.7 cents per share, the placement represents a 19% discount to the company’s 15-day volume-weighted average price (VWAP) of 2.1 cents.
Proceeds will be directed towards expanding the HeraCARE platform into large healthcare systems, private clinics and platforms across the US, Australia and Europe. This includes support for commercial deployments, pilot programs and technology integration.
The platform continues to grow and the company recently set a new record number of active and accumulated users with in excess of 3,800 expectant mothers as at September 30, 2024.
Gungadin highlighted the significance of this funding in enhancing HeraCARE’s reach amid global challenges in maternity care access.
Recent successful implementations, including at Broward Health in the US, underscore the platform’s viability.
Funds will also support further evidence-based research, strategic partnerships and grant applications as HeraMED pursues its Four-Point Strategic Plan.
